Clinical Research Directory
Browse clinical research sites, groups, and studies.
Combined Use of Bacteroides Fragilis and BCAAs on HBsAg Clearance
Sponsor: First Affiliated Hospital of Fujian Medical University
Summary
The goal of this prospective observational study is to determine the effects of concomitant administration of Bacteroides fragilis and Branched-Chain Amino Acids on hepatitis B virus clearance. The primary question it aims to answer is whether this concomitant administration can promote HBV clearance. The study will observe the HBV clearance rate in chronic hepatitis B patients who receive Bacteroides fragilis and BCAA as a supplement to their routine antiviral therapy. For comparison, researchers will compare the clearance rate in this group to that observed in a control group of chronic hepatitis B patients receiving a standard antiviral regimen based on PegIFNα2b and nucleoside analogs.
Official title: A Prospective Observational Study on the Effects of Concomitant Administration of Bacteroides Fragilis and Branched-Chain Amino Acids on HBsAg Clearance
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
40
Start Date
2025-06-01
Completion Date
2026-12-01
Last Updated
2025-12-02
Healthy Volunteers
No
Conditions
Interventions
PegIFNα2b+Nucleoside analog
The patients receive both PegIFNα2b and Nucleoside analog therapy.
PegIFNα2b+Nucleoside analog+Bacteroides fragilis+Branched-Chain Amino Acids
The patients received the concomitant administration of Bacteroides fragilis and BCAA, supplemented to their ongoing combination therapy with PegIFNα2b and Nucleoside analog.
Locations (1)
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China